ABSTRACT Background Real‐world data on low‐dose emicizumab in young children with hemophilia A are limited. Methods This multicenter retrospective study included 26 children (median age: 2.2 years) receiving individualized low‐dose emicizumab (2019–2025). Results Over 48 months, the annualized bleeding rate decreased from 5.31 to 0.60 ( p < 0.001); the median maintenance dose was 0.81 mg/kg/week. FVIII equivalent levels correlated with dose (Quality of life CHO‐KLAT) improved from 57.2 to 69.8 ( p < 0.001). Subclinical joint changes progressed despite bleeding control. No thrombotic events occurred. Conclusions Low‐dose emicizumab effectively reduces bleeding and improves quality of life, supporting its feasibility in resource‐limited settings. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Zhou et al. (Mon,) studied this question.